Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59 myeloma patients in relapse were evaluated for several resistance parameters: expression of p-glycoprotein (MDRl), doxorubicin (Adriamycin) and vincristine sensitivity, and the ability of added verapamil to reduce resistance t o the cytotoxic agents. We found that verapamil was capable of sensitizing myeloma cells that exhibited resistance t o doxorubicin and vincristine in vitro, but did not enhance sensitivity of cells that were drug sensitive (P < .OOl). Myeloma cells expressing MDRl immunohistochemically tended t o be more doxorubicin resistant in vitro than MDR1-negative cells. In the clinical trials, 22 patients with myeloma refractory to vincristine-Adriamycindexamethasone (VAD) were treated with VAD plus high-dose intravenous verapamil (Ve). Among the 22 patients treated with VADIVe, five achieved a partial remission (23%). The median relapse-free survival for the VADIVe responders was 5.4 months and their overall survival from the start of VADIVe was better than that of the nonresponders. Among ULTIPLE MYELOMA is a disseminated plasma cell M neoplasm that exhibits initial sensitivity to alkylating agent-based systemic chemotherapy in most patients. Subsequently, drug resistance usually develops. The VAD regimen, comprised of vincristine (VCR), doxorubicin (DOX), Adriamycin, and dexamethasone, has been useful to reinduce remission in patients who relapse after initial alkylating-agent therapy.' While the VAD regimen is active in up to 70% of myeloma patients refractory to, or relapsing after, initial therapy, drug resistance subsequently appears and patients go on to die of VAD-refractory myeloma.
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We have focused on mechanisms of drug resistance in myeloma and related B-cell neoplasms to develop alternative therapeutic strategies to circumvent drug resistance. One mechanism of drug resistance that appears to be relevant to patients with myeloma is multidrug resistance (involving the MDRl gene product) as described in experi-the subset of 10 patients whose myeloma cells were MDRl positive, four responded clinically (SO%), whereas none of five patients with MDRI-negative myeloma cells achieved remission with VADIVe. We also observed that myeloma cells from three of four VAD/Ve clinical responders exhibited in vitro chemosensitization with verapamil, whereas in vitro verapamil chemosensitization was seen in only one of six clinical nonresponders. Our observations demonstrate that clinical reversal of multidrug resistance can be achieved in some patients with VAD-refractory myeloma with the use of verapamil. In addition to their value in drug development, in vitro tests of MDRl expression and of chemosensitizers plus cytotoxic drugs on the patients' bone marrow myeloma cells may identify patients who will respond clinically t o chemosensitizer-containing regimens. We anticipate that chemosensitizer regimens capable of inhibiting multidrug resistance will play an increasing role in the treatment of hematologic malignancies, including B-cell neoplasms such as multiple myeloma and the non-Hodgkin's lymphomas. 0 1991 by The American Society of Hematology. mental systems.'" It is believed to be mediated by a drug-transporter, active efflux pump called the P-glycoprotein.'.' The P-glycoprotein is a 170-Kd glycoprotein that mediates multidrug resistance (MDR1) and is predominantly distributed in the cell membrane: MDRl is capable of reducing intracellular drug concentrations by increasing the efflux of a variety of different heterocyclic anticancer drugs from neoplastic cells, thereby reducing their cytotoxic potential. Molecular studies in which the MDRl gene is transfected into sensitive cells in culture renders them multidrug resistant, thus confirming the role of the MDRl gene in drug resi~tance.'.~ In our studies to date, we have found MDRl to be commonly expressed in tumor cells from patients with refractory myeloma, whereas its expression is distinctly uncommon in previously untreated patients."-" Moreover, in a recent correlative study, we found an association between MDRl expression and in vitro resistance to DOX in patients with myeloma, lymphoma, and breast cancer in the human tumor colony assay (HTCA)." Inasmuch as resistance in HTCA has been correlated with clinical treatment failure with cancer chemotherapy, the predictive potential of MDRl expression can be anticipated.'* The initial identification of verapamil (Ve) as an agent capable of reversing vinblastine resistance in a murine lymphoid leukemia-lymphoma in vivo was reported by Tsuruo et al.I3 At the time of his original observation, the relationship of this Ve effect to MDRl expression had yet to be identified. Subsequently, a number of investigators have reported that Ve and other noncytotoxic agents can serve as chemosensitizers in vitro and block the drug transport function of the P-gly~oprotein.'~-'~ Several agents, including Ve, quinidine, and quinine have been determined by photoaffinity labeling studies to bind directly to MDR1" and presumably block cytotoxic drug binding and efflux through a competitive inhibition mechanism. We have previously reported our initial pilot clinical studies in which six patients with myeloma and one with lymphoma in relapse after multiple chemotherapy combinations including VAD were treated with VAD plus high-dose intravenous (IV) Ve, with re-establishment of remission in several of the patients?' Of the six myeloma patients included in that report, VAD resistance was circumvented in two of the patients who went back into remission when Ve was added to VAD. The ability of Ve to increase the intracellular accumulation of vincristine or DOX within MDR1-positive myeloma cells was demonstrated in vitro for several patients in the pilot trial. In the current report, we examined in vitro chemosensitization with Ve and correlated this effect and MDRl expression with clinical response to VAD/Ve in VAD-refractory myeloma patients. These studies provide both laboratory and clinical evidence for the potential utility of chemosensitizers in the treatment of patients with drug-resistant multiple myeloma.
MATERIALS AND METHODS

Myeloma cell collection.
Bone marrow aspirates from 59 patients with multiple myeloma were collected with a portion of the aspirate obtained in a syringe containing nontoxic heparin. The portion of the marrow aspirate obtained without heparin was sent for standard histopathologic examination and the heparinized portion sent for specialized testing. The heparinized portion was delivered promptly to the research laboratory wherein tumor cell suspensions were prepared under aseptic conditions.22 An aliquot of the myeloma cell suspensions was used to prepare cytospin slides, which were provided to the immunopathology laboratory for immunohistochemical determination of MDRl expression, and the remainder used for drug sensitivity testing in HTCA. Not all patients' bone marrow aspirates were referred for all tests performed, and some samples were inadequate to yield results. Therefore, reports for specific determinations are reported on subsets of the 59 patients from whom bone marrow aspirates were obtained.
Immunoh~tochemicalstudies. For determination of p-glycoprotein expression, specific monoclonal antibodies (MoAbs) to MDRl were used, including the JSB-1 antibody developed at the Free University of Amsterdam23 (now available commercially from Sanbio (Amsterdam, Netherlands) and the C219 antibody that was originally developed by Gerlach et alZ4 and obtained commercially from Centocor (Malvern, PA). Details of our immunohistochemical methods have been reported previously.'"'2 In these studies, the staining reaction was calibrated with simultaneously stained positive and negative control myeloma cell lines with known degrees of DOX resistance and MDRl expression (as determined in total cellular RNA expression), and MoAb staining.= All slides were carefully reviewed by one of us, who is an immunopathologist (T.M.G.), and scored independently of any knowledge of the patient's clinical condition or of results from in vitro drug sensitivity testing. To be called positive, myeloma cells in the patient's cytospin exhibited 1+ to 3+ positivity in at least 30% of the tumor cells. More infrequent staining (< 30%) was not observed in this study set. In each instance, the staining intensity for p-170 on patient cells was compared with a graded staining reaction in control slides prepared simultaneously with myeloma cell lines expressing either DOX sensitivity, or 6-fold, 10-fold, or 40-fold DOX resistance.
Drug sensitivity testing for DOX and VCR and the effects of the chemosensitizing effect of Ve were determined on the fresh myeloma cell suspensions. These tests
In vifro sensitivity testing.
were conducted in a human tumor colony assay according to standardized procedures for plating tumor cells in semisolid agarose in the presence of complete medium containing 10% fetal calf serum.12.26-M Sensitivity to DOX and VCR was assessed by adding these drugs to the cultures over a several-log range. Ve was also tested separately for possible cytotoxicity in the absence and in the presence of DOX or VCR. Ve was tested at a fixed concentration of 1.0 pg/mL. This Ve concentration was selected for in vitro testing of the sensitizers because it was noncytotoxic in vitro and was clinically achievable in vivo in the plasma of lymphoma patients treated with chemotherapy plus Ve." All drugs were tested by continuous exposure in the soft agarose cultures. Triplicate 0.5-mL cultures containing 100,000 cells were prepared for control and drug-containing cultures at each dosage level and incubated for 96 hours. Using a modification of the HTCA procedure reported by Tanigawa et al,29 tritiated thymidine was added at a final concentration of 10 pCi/mL to each culture for an additional 48 hours, at which time the cultures were harvested for liquid scintillation counting of tritiated thymidine incorporation into acid-precipitable DNA.
Results of drug sensitivity testing on each patient's cells were expressed by determining the IC50 for DOX and VCR (concentration of the drug reducing clonal proliferation to 50% of control) from the drug-inhibition curves. Sensitivity to DOX was defined as an IC50 of less than .01 pg/mL, and to VCR as an IC50 of less than .001 pgimL. To evaluate chemosensitizing effects of Ve, the dose-modifying factor (DMF) attributable to the sensitizer was determined by dividing the IC50 for the cytotoxic drug alone by the IC50 of the cytotoxic drug plus the Ve. DMF values > 4 were operationally defined to indicate significant chemosensitization.
Consenting patients with VAD-refractory multiple myeloma who were evaluated at the Arizona Cancer Center (Tucson) were eligible for investigational therapy with VAD plus Ve in accord with protocols approved by the Human Subjects Committee of the University of Arizona. VAD-refractoriness was defined as tumor progression after one course of the VAD regimen, or as a lack of clinical response to VAD or relapse after at least two successive courses of VAD at 3-to 4-week intervals.
The VAD regimen was administered as described by Barlogie et al,' with the exception that the additional pulses of dexamethasone between courses of VAD were sometimes omitted, particularly in patients with intolerance to high-dose dexamethasone. VCR (0.4 mgid) and DOX (9 mgim'id) were both administered for 4 days by continuous IV infusion through a central venous access line, along with oral dexamethasone at a dose of 40 mgid for the 4-day period.
The IV formulation of Ve (Isoptin) used in this study was kindly provided by Knoll Pharmaceuticals (Whippany, NJ). As described previously," Ve was administered by continuous IV infusion in the cardiac monitoring unit at University Hospital starting 12 hours before the initiation of VAD therapy and continuing for a total of 5 days of Ve administration. The Ve dosage was started at a dose rate of 0.15 mgkgh and escalated at 24-hour intervals based on individualized patient tolerance, usually up to a maximum of 0.45 mgkgih. Plasma samples for Ve and norverapamil concentrations were obtained on day 4 of the infusion and determined by high-pressure liquid chromatography. Of the 22 patients whose treatment results with VADNe are included in the current report, data on six of them were reported previously.*' Ve was discontinued if the patient's blood pressure decreased to less than 90 mm Hg or if second-or third-degree heart block developed. Once the toxicity had resolved, Ve therapy was resumed at a dose that was 50% of the prior dose rate.
Clinical response to therapy was determined in accord with standardized myeloma response criteria based on serial quantitative determinations of the patient's myeloma Ig (M-protein) in the Clinical trials.
For personal use only. on August 14, 2017. by guest www.bloodjournal.org From nofixation methodology. Tumor mass regression with therapy was defined in accord with current criteria of the Southwest Oncology Group. Response was defined as a 75% reduction in the rate of serum M-protein production with a serum M-protein, and reduction to less than 200 md24 hours or complete clearing of urinary Bence Jones proteins (BJP). Additionally, other manifestations of myeloma, including bone pain, hypercalcemia, and anemia, had to show at least stability or improvement. The development of new osteolytic lesions was considered to represent progression, but the development of compression fractures without evidence of new osteolytic lesions was not. Partial response (PR) to therapy was defined as a 50% reduction in the production rate of serum M-protein and urinary BJP. Minor reductions (MR) in M-protein production (25% to 50% of pretreatment levels) were recorded, but not classified as responses. Relapse-free and overall survival for all patients and responsive patients was determined from the time that treatment was initiated.
The correlation between IC50 values for DOX in the presence and absence of Ve was evaluated using the Pearson correlation coefficient. The Spearman rank correlation coefficient was also used because it is less sensitive to extreme values. Comparisons of in vitro results and of some in vitro and in vivo results were evaluated in 2 x 2 contingency tables using Fisher's exact test. Survival curves for patients treated with VADNe were generated using the Kaplan-Meier estimator?* Comparisons between curves were evaluated using the log-rank t e~t . 3~ AllP values reported are two-tailed.
Statistical analysis.
RESULTS
P-glycoprotein expression and in vitro drug resistance.
MDRl expression by myeloma cells had a characteristic cell membrane distribution and occasionally also had a Golgi apparatus distribution. However, membrane staining was specifically required for the staining reaction to be called positive. As assessed by comparison to simultaneously stained myeloma cell lines with graded degrees of DOX resistance, MDRl staining on fresh specimens usually approximated with about sixfold resistance on the cell lines, or a 1+ staining reaction. The expression of MDRl by myeloma cells and its relation to in vitro DOX resistance was evaluated on bone marrow aspirates from 30 patients. Among the 21 patients whose myeloma cells were MDR1-negative, 15 (71%) were sensitive to DOX in vitro. Among the nine patients whose myeloma cells were positive for MDRl expression, only four (44%) were sensitive to DOX In vitro effects of Ve on drug-sensitive and drug-resistant myeloma cells. The chemosensitizing effects of Ve on DOX-and VCR-treated cells and controls were assessed in HTCA and classified in accord with drug sensitivity or resistance of the myeloma cells to the cytotoxic agents. Figure 1 depicts a log-log plot of data on DOX sensitivity in 40 myeloma patients for whom the IC50 was determined for DOX alone and in the presence of 1.0 p.g/mL of Ve. The effect of Ve as a chemosensitizer was the greatest in myeloma cells that showed the greatest degree of DOX resistance. In contrast, there was little or no effect of Ve on myeloma cells that were quite sensitive to DOX alone. When analyzed with correlation techniques, this relationship was statistically significant because the Pearson corre-(P = .22). lation coefficient was .52 (P < .001) and the Spearman rank correlation coefficient was .35 (P = .026).
An alternative method of depicting the in vitro effects of Ve on DOX-and VCR-treated cells is shown in Fig 2. In this analysis, the frequency of significant chemosensitization (DMF > 4) is related to myeloma cell sensitivity or resistance to DOX or VCR alone. As can be appreciated in Fig 2, the chemosensitizing effects of Ve were observed frequently in myeloma cells resistant to DOX or VCR alone as compared with cells that were sensitive to either of these cytotoxic drugs. For the comparison of DOX and Ve (for which there was the largest sample size), this relationship was statistically significant (P < .001). The same trend was seen with VCR (Fig 2) . For all experimental comparisons combined with either DOX or VCR, the addition of Ve produced a highly significant sensitizing effect on the drug-resistant tumor ceils (P < .001). Whereas 15 of 19 (78.9%) of the resistant tumor specimens had a DMF > 4
with Ve, only 3 of 31 (9.7%) of the sensitive tumors had a DMF > 4.
A total of 22 refractory myeloma patients who were treated with VAD plus IV Ve (after failing on VAD alone) were evaluable for therapeutic response. Patient characteristics and response information are summarized in Table 1 .
All 22 patients who received high-dose Ve were hospitalized and treated in cardiac telemetry units at University Medical Center. The maxiClinical trials of chemosensitizers.
VAD plus high-dose Ve.
For personal use only. on August 14, 2017. by guest www.bloodjournal.org Thcrapcutic rcsults with VADNc in rclation to MDRl cxprcssion arc summarizcd in Tablc 1. Of thc 22 paticnts trcatcd with VAD plus Vc. fivc paticnts (23%) achicvcd a partial rcsponsc. Among thc remaining 17 patients. six had minor reductions in M-protein production and 11 showcd no changc or ovcrt progression during thcrapy.
P-glycoprotcin was dctcrmincd immunohistochcmically on boric marrow aspiratcs from 15 of thc patients (68%) bcforc trcatmcnt with VAD plus Vc (Tablc I). Of thcsc, 10 wcrc MDRI-positivc (67%). Among thc 10 MDR1-positivc mycloma patients. four (40%) achicvcd PRs with thc addition of Vc to thc VAD rcgimcn. On thc othcr hand, nonc of thc tivc MDRI-ncgativc paticnts achicvcd PR status with VAD/Vc (P = .23). Of thc scvcn MDRl unknown paticnts. one achicvcd a PR on VADNc. In vitro drug tcsting and dctcrmination of the DMF was pcrformcd bcforc VADNc thcrapy in a total of I O paticnts. DMF values >4 wcrc obtaincd in thrcc of four paticnts who achicvcd PRs on thcrapy. and in only onc of six of thc clinical nonrcspondcrs ( P = .19).
Thc mcdian survival from thc start of VADNc for all 22 paticnts was only 5.1 months. Thc mcdian rclapse-frce intcrval for thc fivc paticnts who wcrc responsive to VADNc was 5.4 months. Thc mcdian survival for thc fivc responders was 13.5 months in comparison with 3.4 months for thc nonrcspondcrs (P = .I I).
DISCUSSION
In the currcnt study wc cxtcndcd our clinical cxpcricncc with VADNc as wcll as pcrforming rclcvant in vitro obscwations on MDR 1 cxprcssion and chcmoscnsitization. Thc frcqucncy of rcsponsc to VADNc (5 of 22 paticnts or 23%) is consistent with thc rcsponsc of two of six paticnts in our original pilot study. Thc original pilot study also rcportcd an objcctivc rcsponse in a single lymphoma paticnt. Morc rcccntly wc pcrformcd a phasc 11 cvaluation of cyclophosphamidc plus VAD (CVAD) along with highdow IV Vc (as uscd in myeloma) in 18 paticnts with hcavily prctrcatcd and drug-rcsistant lymphoma." Thirtccn of thcsc paticnts (73%) wcrc brought back into at lcast partial rcmission with thc usc of thc same Vc rcgimcn. with fivc of thc paticnts (28%) achicving complctc rcmissions. As was obscrvcd in thc currcnt mycloma study, thc rcsponscs wcrc somcwhat morc frcqucnt in lymphoma paticnts w h m biopsics wcrc immunohistochemically positivc for MDRI. Thc objcctivc rcsponsc ratc of lymphoma paticnts whom we trcatcd with CVADNc was significantly highcr than was obtaincd in mycloma with VADNc. Whilc wc rccognizc that many factors, including tumor typc and cyclophcwphamidc administration, may account for this ditTcrcncc in rcsponsivcncss, Vc tolcrancc may also bc an important factor. Pcrhaps in part bccausc thc lymphoma paticnts wcrc significantly youngcr. thcy tolcratcd significantly highcr dosagcs of IV Vc than did thc paticnts with mycloma. Tol- erance was reflected in part by the median plasma concensample size and drug concentrations tested in these compartrations of Ve, which were normally determined on day 4 of isons, the in vitro test results must be considered only the infusions. Among the 18 lymphoma patients tested, the suggestive. Additional in vitro studies using lower Ve median plasma Ve concentration was 1,022 ng/mL," whereas concentrations are warranted. When we initiated our in among the 20 myeloma patients tested in the current study vitro studies we had anticipated that concentrations of 1.0 the median Ve concentration was 295 ng/mL. pg/mL would be achievable in myeloma as they had been in MDRl expression has been reported to be present the lymphoma patients. The plasma Ve concentrations constitutively or is acquired after drug exposure in various achievable with IV Ve in the myeloma patient population forms of human cancer.3sr36 Our selection of B-cell neowe studied were similar to those achievable with oral plasms such as myeloma and lymphoma for clinical trials of administration. Accordingly, the study of this regimen to be chemosensitizers was based not only on evidence of P-glycoconducted in the Southwest Oncology Group uses oral protein expression, but also on the original observation by administration of a sustained action Ve formulation. FurTsuruo et all3 that Ve could reverse vinca alkaloid resisthermore, in vitro sensitivity testing cannot mimic the in tance in a murine lymphoma/leukemia model. vivo situation with multiple cytoxic drugs, metabolism, and In this report, several new laboratory observations on other variables. clinical drug resistance have been described. In the in vitro
The level of sensitivity that we currently have in the studies we found that Ve exerted its chemosensitizing immunohistochemical detection of MDRl expression is in effects selectively on DOX-or VCR-resistant cells (Figs 1 the range of a fourfold to sixfold expression of DOX and 2). Inasmuch as Ve binds to P-glycoprotein? it resistance as determined in studies with MDR-expressing appears likely that its chemosensitizing effect is mediated myeloma cell lines.'o~l' Based on our in vitro comparisons, by competitively inhibiting cytotoxic drug efflux mediated we suspect that in vitro chemosensitization with Ve in by the MDRl transporter pump. The correlations that we HTCA or by flow cytometry may be a somewhat more obtained between the vitro tests of drug resistance and the sensitive test for the presence of functional P-glycoprotein clinical outcome of therapy suggest that both immunohisthan is immunohistochemistry. On the other hand, the tochemical testing and in vitro chemosensitization may immunohistochemical procedure for MDRl expression is prove to be useful tests for identifying myeloma patients far simpler to perform and therefore may be more clinically likely to respond to VAD/Ve. However, due to limited applicable. Unfortunately, some specimens prove unsatisfac- tory for immunohistochemical evaluation, and this was the case in the current study so that correlations were not available in all patients. We have closed our local studies of VAD plus Ve and have initiated a prospective randomized trial in refractory myeloma of VAD alone versus VAD plus oral Ve in the Southwest Oncology Group. This large-scale evaluation will critically evaluate the activity of the Ve as well as of immunohistochemical expression of MDRl.
Ve was selected as the initial chemosensitizers to add to the VAD regimen because it could block multidrug resistance in DOX-resistant, MDR1-expressing human myeloma cell lines derived from the 8226 myeloma line as tested in our laboratories?' Chemosensitizers such as Ve are at best first-generation agents. Ve as marketed is a racemic mixture of s-verapamil and r-verapamil. While s-verapamil is the component predominantly mediating the drug's calcium-channel blocking cardiac effects, the r-enantiomer has approximate1y 80% less cardiovascular effect in preclinical assays. In Contrast to this marked difference in cardiac efforts, r-and s-verapamil as well as the racemic mixture appear to have similar potency in inhibiting the function of P-glycopr~tein.~~ Accordingly, we have recently initiated clinical studies of r-verapamil. Drugs with differing structures are now under evaluation alone and in combination as potential chemosensitizers to inhibit MDRl in various neoplasms including myeloma (eg, ref 39) .
Under optimal circumstances, the use of chemosensitizers in cancer therapy will not be limited to reversing established drug resistance but might also be able to prevent the development of drug resistance when added to initial chemotherapy. We recognize that clinical drug resistance is multifactorial and mechanisms other than MDRl may prove important in multiple myeloma and lymphoma. Nonetheless, our findings suggest that we may be approaching a new era in clinical oncology wherein drug resistance can be effectively circumvented.
